AF
CSTL icon

Amalgamated Financial’s Castle Biosciences CSTL Stock Holding History

Amalgamated Financial’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$152K Buy
+3,397
New +$140K ﹤0.01% 1998

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Amalgamated Financial's CSTL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Castle Biosciences (CSTL) in Q1 2022: 3,397 shares worth $152K. The stake represents ﹤0.01% of the portfolio and ranks #1998 among its holdings.

160 funds tracked by Wall St. Rank hold CSTL as of Q1 2022.

  • Amalgamated Financial held 3,397 shares of Castle Biosciences worth $152K as of Q1 2022.
  • Castle Biosciences was a new Amalgamated Financial position in Q1 2022.
  • Castle Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1998 holding.
  • 160 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.